Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection

Emma D Deeks, Emma D Deeks

Abstract

Bictegravir is a new integrase strand transfer inhibitor (INSTI) with a high genetic barrier to the development of HIV-1 resistance. The drug is co-formulated with the nucleos(t)ide reverse transcriptase inhibitors emtricitabine and tenofovir alafenamide (AF) in a single-tablet regimen (STR) for the once-daily treatment of HIV-1 infection in adults (bictegravir/emtricitabine/tenofovir AF; Biktarvy®). In phase 3 trials, bictegravir/emtricitabine/tenofovir AF was noninferior to dolutegravir-based therapy (dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir AF) in establishing virological suppression in treatment-naïve adults through 96 weeks' treatment and, similarly, was noninferior to ongoing dolutegravir/abacavir/lamivudine or boosted elvitegravir- or protease inhibitor (PI)-based therapy in preventing virological rebound over 48 weeks in treatment-experienced patients. No resistance emerged to any of the antiretrovirals in the STR. Bictegravir/emtricitabine/tenofovir AF is generally well tolerated, requires no prior HLA-B*5701 testing (making it more suitable for 'rapid start' treatment), fulfils the antiretroviral regimen requirement for patients with hepatitis B virus (HBV) co-infection (i.e. contains tenofovir AF and emtricitabine, both of which are active against HBV) and can be used in renally impaired patients with creatinine clearance (CRCL) ≥ 30 mL/min. Thus, although cost-effectiveness analyses would be beneficial, current data indicate that bictegravir/emtricitabine/tenofovir AF is a convenient initial and subsequent treatment option for adults with HIV-1 infection, including those co-infected with HBV, and provides the first non-pharmacologically boosted, INSTI-based, triple-combination STR suitable for patients with CRCL 30-50 mL/min.

Conflict of interest statement

Emma Deeks is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

    1. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2018. . Accessed 30 Oct 2018.
    1. British HIV Association. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. 2015 (2016 interim update). . Accessed 30 Oct 2018.
    1. European AIDS Clinical Society. Guidelines Version 9.1. 2018. . Accessed 30 Oct 2018.
    1. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320(4):379–396. doi: 10.1001/jama.2018.8431.
    1. Anstett K, Brenner B, Mesplede T, et al. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017;14(36):1–16.
    1. Tang Q, Lu H. Latest advances in the efficacy, tolerability, and monotherapy of integrase inhibitors. Biosci Trends. 2017;11(4):490–495. doi: 10.5582/bst.2017.01194.
    1. Sebaaly JC, Kelley D. Single-tablet regimens for the treatment of HIV-1 infection. Ann Pharmacother. 2017;51(4):332–344. doi: 10.1177/1060028016682531.
    1. Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60(12):7086–7097.
    1. Hassounah SA, Alikhani A, Oliveira M, et al. Antiviral activity of bictegravir and cabotegravir against integrase inhibitor-resistant SIVmac239 and HIV-1. Antimicrob Agents Chemother. 2017;61(12):1–9. doi: 10.1128/AAC.01695-17.
    1. Gilead Sciences. Biktarvy 50 mg/200 mg/25 mg film-coated tablets: EU summary of product characteristics. 2018. . Accessed 30 Oct 2018.
    1. Gilead Sciences. Biktarvy® (bictegravir, emtricitabine, and tenofovir alafenamide): US prescribing information. 2018. . Accessed 30 Oct 2018.
    1. Neogi U, Singh K, Aralaguppe SG, et al. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. AIDS. 2018;32(4):469–476.
    1. Smith SJ, Zhao XZ, Burke TR, Jr, et al. Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15(37):1–18.
    1. White KL, Niedziela-Majka A, Novikov N, et al. Bictegravir dissociation half-life from HIV-1 G140s + Q148H integrase/DNA complexes [abstract no. 497] Top Antivir Med. 2017;25(Suppl. 1):204s–205s.
    1. Brenner BG, Oliveira M, Ibanescu RI, et al. In vitro selected resistance to new integrase inhibitors by B & non-B subtype viruses [abstract no. 549] Top Antivir Med. 2018;26(Suppl. 1):233s.
    1. US FDA. Application number: 210251Orig1s000 multi-discipline review. 2017. . Accessed 30 Oct 2018.
    1. Oliveira M, Ibanescu RI, Anstett K, et al. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 2018;15(1):56. doi: 10.1186/s12977-018-0440-3.
    1. Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073–2082. doi: 10.1016/S0140-6736(17)32340-1.
    1. Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063–2072. doi: 10.1016/S0140-6736(17)32299-7.
    1. Daar ES, De Jesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e347–e356. doi: 10.1016/S2352-3018(18)30091-2.
    1. Molina J-M, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e357–e365. doi: 10.1016/S2352-3018(18)30092-4.
    1. Kityo C, Hagins D, Koenig E, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide in women [poster no. 500]. In: Conference on Retroviruses and Opportunistic Infections. 2018.
    1. Acosta R, White K, Garner W, et al. HIV-1 subtype (B or non-B) had no impact on the efficacy of B/F/TAF or resistance development in five phase 3 treatment-naive or switch studies [abstract no. THPEB077]. In: 22nd International AIDS Conference. 2018.
    1. Zhang WW, Cheung PK, Oliviera N, et al. Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors. J Infect Dis. 2018;218(11):1773–1776. doi: 10.1093/infdis/jiy428.
    1. Milburn J, Jones R, Levy JB. Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant. 2017;32(3):434–439.
    1. Zhang H, West S, Vu A, et al. A study evaluating the pharmacokinetics, safety, and tolerability of the bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) single tablet regimen (STR) in Japanese subjects [abstract no. MOPEB0332]. In: 9th International AIDS Society Conference on HIV Science. 2017.
    1. Wohl DA, Yazdanpanah Y, Baumgarten A, et al. A phase 3, randomized, controlled clinical trial of bictegravir in a fixed-dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naïve adults at week 96 [abstract no. LB4]. In: IDWeek. 2018.
    1. Stellbrink HJ, Arribas J, Stephens JL, et al. Phase III randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) versus dolutegravir (DTG) + F/TAF in treatment-naïve HIV-1 positive adults: week 96 [abstract plus presentation]. In: HIV Drug Therapy Conference. 2018.
    1. Wohl D, Clarke A, Maggiolo F, et al. Patient-reported symptoms over 48 weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus co-formulated abacavir, dolutegravir, and lamivudine. Patient. 2018;11(5):561–573. doi: 10.1007/s40271-018-0322-8.
    1. Chuck S. Renal data at 96 weeks for study 1490. California: Gilead Sciences. 2018. (Data on file).
    1. Yombi JC, Pozniak AL. Is it time for integrase inhibitors to be the preferred regimen for the first-line treatment of HIV-1-infected naive patients? AIDS Rev. 2016;18(2):89–100.
    1. Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839–849. doi: 10.1016/S0140-6736(17)33095-7.
    1. Norwood J, Turner M, Bofill C, et al. Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527–531. doi: 10.1097/QAI.0000000000001525.
    1. Bakal DR, Coelho LE, Luz PM, et al. Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors. J Antimicrob Chemother. 2018;73(8):2177–2185. doi: 10.1093/jac/dky145.
    1. European Medicines Agency. New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir [media release]. . Accessed 18 May 2018.
    1. ViiV Healthcare UK Ltd. Triumeq 50 mg/600 mg/300 mg film-coated tablets: EU summary of product characteristics. 2018. . Accessed 30 Oct 2018.
    1. ViiV Healthcare UK Ltd. Juluca 50 mg/25 mg film-coated tablets: EU summary of product characteristics. 2018. . Accessed 30 Oct 2018.
    1. ViiV Healthcare. Juluca (dolutegravir and rilpivirine) tablets, for oral use: US prescribing information. 2018. . Accessed 30 Oct 2018.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner